Advanced search×

Lung cancer after treatment for breast cancer

Lancet Oncol 11(12):9 (2010) PMID 20541465

Breast cancer is the most common cancer in women, and the second most common cause of cancer death after lung cancer. Improvements in the outcome of breast cancer mean that more patients are living longer and are, therefore, at risk of developing a second malignancy. The aim of this review is to present the current understanding of the risk of lung cancer arising in patients previously treated for early stage breast cancer. We review data on the effect of treatment factors (ie, surgery type, radiotherapy technique, and adjuvant chemotherapy) and patient factors (ie, age and smoking) on the risk of developing a subsequent lung cancer. The evidence suggests that older radiotherapy techniques were associated with a substantially increased risk of developing lung cancer in the ipsilateral lung, but there is no clear evidence of an increased risk with modern techniques. Smoking is an important risk factor, and increases the risk of lung cancer in those receiving radiotherapy. Adjuvant chemotherapy is not significantly associated with an increased risk. The risk of developing lung cancer increases with time elapsed since treatment, but any effect of age at treatment is unclear.

Copyright © 2010 Elsevier Ltd. All rights reserved.

DOI: 10.1016/S1470-2045(10)70056-5
Version: za2963e q8zac q8zbe q8zc0 q8zd2 q8ze8 q8zf5 q8zga

Similar articles you may find interesting…

  1. A novel role for Sema3A in neuroprotection from injury mediated by activated microglia.

    J Neurosci 26(6):1730-8 (2006) PMID 16467521

    We found that activation of microglia by IFNgamma induced differential upregulation of the semaphorin receptors Plexin-A1 and Neuropilin-1. This result was confirmed by Northern blotting, reverse transcription-PCR, and Western blotting. Furthermore, recombinant Sema3A induced apoptosis of microglia...
  2. Multiple sclerosis.

    Clin Evid (Online) (2007) PMID 19454107

    We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of: interventions aimed at reducing relapse rates and disability; interventions to improve symptoms during acute relapse; treatments for fatigue; treatments for spasticity; and multidisciplina...
  3. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis.

    Brain Pathol 19(2):238-53 (2009) PMID 18492094

    Our study provides evidence of substantial archaeocortical pathology largely resembling patterns seen in the neocortex and suggests that hippocampal involvement could contribute to memory impairments often seen in MS....